NASDAQConsumer StaplesHousehold & Personal ProductsSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SLSN yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Stabilize leadership and management execution | A supporting condition in Solesence, Inc.'s published investment case. The stated target is No further major leadership departures. | Intact | Additional key executive departures occur | 0 key executive departures vs 0 allowed News and events show financial and regulatory issues but no reports of key executive departures. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 10, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk turnaround-style business with some growth and operating improvement, rather than an established, consistent compounder. The long-term thesis is still in a watch state: recent progress is visible, but financial performance remains weak and below its industry cohort.
Valuation is expensive versus peers, and its valuation measure rose from 27.5 to 39.5. The expectations gap is flagged as unjustified, though model confidence is low; the evidence does not specify exactly what growth the market assumes.
Near-term results show revenue and gross profit increased from the first to the second quarter of 2026, while operating income moved from a loss to a small profit. Management is making progress on strategic execution, but financial discipline is mixed, and past financial statements were subject to a non-reliance notice; a guidance cut remains a risk.
Over the next few quarters, the thesis depends on continued revenue growth, stronger operating income, and reliable financial reporting. A guidance cut or further weakness in jobs data could weigh on the business outlook, while continued earnings strength and higher guidance from sector peers could support the sector backdrop.
For the next 1 to 3 years, SLSN offers signs of operational progress, but the weak performance record, elevated risks, and expensive valuation leave the long-term thesis unproven. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Solesence aims to improve its operating income after recent losses. |
| Broken |
| Operating income remains negative over next 4 quarters |
Operating income: $121,000 FY2026-Q2; GAAP. Published target: Operating income > $0. Target period is not explicitly aligned with this observation. Aug 19, 2026121,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 1 supplied quarters. Management reported: “Laura Riffner, Chief Financial Officer, added, “In the first quarter, Solésence’s investments focused on its operational infrastructure, including employee training and organizational restructuring which created near-term pressure on profitability but also resulted in improved efficiency and reduced labor costs across the business.” “Combined with our targeted operational efficiency initiatives, these efforts ensure Solésence remains lean, agile, and structured for long-term value creation.”” Operating income was $0.121 million in 2026-Q2. Delivery assessment Nov 4, 2026 |
Maintain revenue near $64 million in 2025 | Revenue is expected near $64 million in 2025. | Broken | Revenue falls below $64 million in FY25 | Revenue: $15.332M FY2026-Q2; GAAP. Published target: Revenue >= $64 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 19, 202615,332,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.